API contract manufacturing: Process, benefits, and partner selection

Manufacturing active pharmaceutical ingredients (APIs) is a complex undertaking that requires specialized process knowledge, advanced manufacturing capabilities, and robust quality and regulatory systems. As drug molecules become increasingly advanced and regulatory expectations continue to evolve, many pharmaceutical and biotechnology companies partner with contract development and manufacturing organizations (CDMOs) to support the development, scale-up, and commercial production of APIs.

API contract manufacturing encompasses a broad range of activities, from process and analytical development to technology transfer, GMP manufacturing, and commercial supply. By leveraging the expertise, infrastructure, and established quality systems of experienced manufacturing partners, companies can accelerate development timelines, access specialized technologies, and secure a reliable path to market. This article explores the role of API contract manufacturing, key considerations when outsourcing API production, and the factors that differentiate a strong manufacturing partner.

What is API contract manufacturing?

An API is the biologically active component in a drug that produces its intended therapeutic effect. As pharmaceutical pipelines increasingly include complex modalities such as peptides and oligonucleotides, the development and manufacture of APIs require specialized process expertise, advanced manufacturing technologies, and robust quality systems.

API contract manufacturing involves outsourcing the development, scale-up, and/or production of APIs to specialized external partners. These organizations may operate as Contract Manufacturing Organizations (CMOs), focused primarily on manufacturing services, or as Contract Development and Manufacturing Organizations (CDMOs), which provide broader support across development and commercialization.

While cost and capital efficiency remain important considerations, outsourcing is increasingly driven by the need for specialized expertise, access to advanced technologies, manufacturing flexibility, and established regulatory and quality capabilities. Partnering with an experienced manufacturer allows pharmaceutical and biotech companies to immediately tap into an agile and established infrastructure, helping accelerate development timelines, mitigate scale-up risks, and support reliable supply throughout the product lifecycle.

The API contract manufacturing process

The API contract manufacturing process varies depending on the molecule, technology platform, development phase, regulatory strategy, and intended scale. While no single workflow applies to every program, most API manufacturing projects follow a structured progression from technical assessment and process development through scale-up, GMP manufacturing, regulatory support, and controlled supply.

For complex APIs, including peptides and oligonucleotides, this process is rarely linear. Process development, analytical development, quality oversight, and regulatory documentation often advance in parallel to ensure that the manufacturing process is scalable, controlled, and suitable for clinical or commercial use.

1. Project assessment & early development

API manufacturing projects typically begin with an assessment of the molecule, synthesis route, analytical methods, manufacturing requirements, and supply chain considerations. During early development, scientists evaluate process feasibility, assess the availability and sourcing of critical raw materials or building blocks, identify potential scale-up challenges and generate material for preclinical or early clinical studies.

At this stage, the focus is on building process understanding, identifying supply chain risks and establishing a foundation for robust manufacturing and analytical control.

2. Process development & optimization

Process development focuses on establishing or refining a manufacturing approach that can be performed reproducibly at the required scale and quality. The objective is to increase yield, control impurities, and develop a process that can be reliably transferred from the laboratory to larger manufacturing environments.

For complex APIs such as peptides and oligonucleotides, process optimization may involve refining synthesis strategies, improving purification performance, reducing solvent consumption, and strengthening process controls to support larger-scale production.

3. Analytical development & quality control strategy

Analytical development is central to API manufacturing and progresses alongside process development. Robust analytical methods are required to confirm identity, purity, assay, impurity profiles, stability, and other critical quality attributes.

Robust quality control systems are essential to uphold compliance with pharmacopeial standards and broader regulatory expectations. Quality control activities include the testing and evaluation of critical quality attributes such as identity, purity, assay, stability, and impurity profiles to ensure APIs consistently meet predefined specifications.

4. Pilot production & scale-up

Following successful process refinement, manufacturing moves from pilot to larger-scale production. This stage is designed to confirm that the process can perform consistently at larger volumes, while identifying any operational or quality challenges before commercial manufacturing.

Technology transfer is often a key component of this phase. Effective knowledge transfer, process documentation, and cross-functional collaboration help ensure a smooth transition into larger-scale manufacturing.

5. GMP manufacturing

GMP manufacturing involves producing the API under controlled conditions for clinical or commercial use. Manufacturing operations must consistently deliver material that meets predefined quality specifications while complying with applicable regulatory requirements. An established quality system supports this through oversight of documentation, process execution, material traceability, defining limits and the review as well as release of manufacturing data. As development progresses from early clinical studies to commercial supply, processes and analytical methods become increasingly established, leading to extensive validation activities and heightened expectations for regulatory compliance, supply security, and consistent product performance.

6. Regulatory support: strategy, documentation, submission & maintenance

Companies applying for clinical trials or commercial licenses require data from their CDMO to fill the quality part of the Common Technical Document (CTD). CDMOs support applicants in preparing this document by providing or collaboratively drafting CTD sections related to their product. They may also provide the corresponding technical reports and data (e.g. on method and process validations, material characterization) to their customers, as a basis for the dossier writing.

Integrated regulatory support is available throughout the API lifecycle, from early development and clinical phases through commercial manufacture and post-approval changes.

7. API release, packaging, storage & distribution

After manufacturing and quality control testing are complete, the API is released according to approved specifications and quality procedures. Final packaging, labelling, storage, and shipment must be designed to protect product quality, stability, and traceability.

Depending on the molecule type, this may involve temperature-controlled storage, specialized containment systems, tamper-evident packaging, and tightly-managed logistics processes to ensure safe delivery throughout the supply chain.

Why companies choose to outsource API manufacturing

API manufacturing requires specialized scientific expertise, advanced technologies, experienced personnel, and robust quality and regulatory systems. Outsourcing manufacturing to CDMOs allows pharmaceutical and biotech companies to access these capabilities while reducing operational complexity and development risk.

One of the main advantages of API contract manufacturing is access to specialized expertise. Experienced manufacturing partners bring deep knowledge in process development, scale-up, analytical sciences, quality control, regulatory compliance, and commercial manufacturing. This expertise can help accelerate development timelines, address technical challenges, and support a smoother path to commercialization.

Outsourcing also provides access to established infrastructure and manufacturing technologies without the significant capital investment required to build and maintain GMP-compliant facilities. This can be particularly valuable for complex APIs that require specialized equipment, containment strategies, advanced purification technologies, or dedicated analytical capabilities.

Scalability is another major contributing factor. Manufacturing partners can provide support to programs as they move from early clinical development to commercial supply, allowing companies to adjust production volumes without requiring investment to internal infrastructure.

In addition, experienced CDMOs often bring established supply chains, proven manufacturing platforms, and mature quality systems that can help mitigate risk and improve operational efficiency. This allows companies to focus on other activities such as research, clinical development, and portfolio growth while leveraging external expertise to support successful product development and commercialization.

Key considerations when selecting an API contract manufacturer

Choosing the right API manufacturing partner is critical to long-term success. Companies should consider partners with the right technical expertise, quality systems, regulatory experience, and supply chain reliability.

1. A strong regulatory track record

Proven experience complying with industry regulations is essential. Manufacturers should operate under GMP standards and demonstrate experience cooperating with inspections from agencies such as the FDA and EMA. Clear documentation practices and robust quality management systems are equally important for maintaining compliance throughout development and commercial supply.

2. Technical capability

Manufacturing requirements vary significantly across different API modalities. Companies should ensure their manufacturing partner has experience relevant to the molecule and program scale.

3. Scalability

A manufacturing partner should be able to support programs as they progress from clinical development to commercial production. Beyond capacity, companies should evaluate the partner’s ability to scale processes efficiently while maintaining process robustness, and supply continuity as demand grows.

4. Collaboration and communication

Effective collaboration and transparent communication can have a major impact on the success of a project. Clearly defined technology transfer processes, strong project management, and open communication channels help reduce risk, improve decision-making, and facilitate efficient progression through development and manufacturing.

5. Supply chain and operational resilience

Reliable manufacturing depends on more than production capabilities alone. Companies should assess how potential partners manage raw material sourcing, supplier qualification, inventory strategies and logistics. For complex APIs, such as peptides and oligonucleotides, that rely on specialized raw materials or building blocks, proactive supply chain management can play a critical role in mitigating risk and safeguarding long-term supply.

Why partner with Bachem for API contract manufacturing?

Bachem combines decades of experience in peptide and oligonucleotide manufacturing with integrated CDMO and CMO capabilities.

With global manufacturing infrastructure, advanced analytical expertise, and experience supporting complex APIs at scale, Bachem helps pharmaceutical and biotech companies navigate the challenges of modern API manufacturing with confidence.

From early-stage development through to large-scale commercial production, Bachem’s focus on quality, regulatory compliance, and supply reliability supports efficient development pathways and long-term manufacturing success.

Contact Bachem today to learn how we can help.